The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Open accessAbstract
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic. In this work, we developed a nucleoside-modified messenger RNA (mRNA)–lipid nanoparticle vaccine encoding hemagglutinin antigens from all 20 known influenza A virus subtypes and influenza B virus lineages. This multivalent vaccine elicited high levels of cross-reactive and subtype-specific antibodies in mice and ferrets that reacted to all 20 encoded antigens. Vaccination protected mice and ferrets challenged with matched and mismatched viral strains, and this protection was at least partially dependent on antibodies. Our studies indicate that mRNA vaccines can provide protection against antigenically variable viruses by simultaneously inducing antibodies against multiple antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
Katoh, K. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf436 · Cited by 17,027
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era
Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa015 · Cited by 16,873
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationNextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 699
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Self-citationA facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Self-citationPardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
Self-citationSARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 529
Recent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512
Self-citationErbelding, E. J., Post, D. J., Stemmy, E. J., Roberts, P. C., Augustine, A. D., Ferguson, S., Paules, C. I., Graham, B. S., & Fauci, A. S. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy103 · Cited by 438
Influenza Research Database: An integrated bioinformatics resource for influenza virus research
Zhang, Y., Aevermann, B. D., Anderson, T. K., Burke, D. F., Dauphin, G., Gu, Z., He, S., Kumar, S., Larsen, C. N., Lee, A. J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw857 · Cited by 342
Nachbagauer, R., Feser, J., Naficy, A., Bernstein, D. I., Guptill, J., Walter, E. B., Berlanda-Scorza, F., Stadlbauer, D., Wilson, P. C., Aydillo, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1118-7 · Cited by 337
Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299
Self-citationPardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
Self-citationThe evolution and future of influenza pandemic preparedness
Harrington, W. N., Kackos, C. M., & Webby, R. J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00603-0 · Cited by 279
Whittle, J. R. R., Wheatley, A. K., Wu, L., Lingwood, D., Kanekiyo, M., Ma, S. S., Narpala, S. R., Yassine, H. M., Frank, G. M., Yewdell, J. W., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03422-13 · Cited by 247
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
McLean, G., Kamil, J., Lee, B., Moore, P., Schulz, T. F., Muik, A., Sahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 194
He, W., Tan, G. S., Mullarkey, C. E., Lee, A. J., Lam, M. M. W., Krammer, F., Henry, C., Wilson, P. C., Ashkar, A. A., Palese, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609316113 · Cited by 182
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
(2022) · doi:10.1016/j.cell.2022.01.027 · Cited by 179
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
Nachbagauer, R., Choi, A., Hirsh, A., Margine, I., Iida, S., Barrera, A., Ferres, M., Albrecht, R. A., García-Sastre, A., Bouvier, N. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3684 · Cited by 172
Laidlaw, B. J., Decman, V., Ali, M. A., Abt, M. C., Wolf, A. I., Monticelli, L. A., Mozdzanowska, K., Angelosanto, J., Artis, D., Erikson, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003207 · Cited by 146
Corbett, K. S., Moin, S. M., Yassine, H. M., Cagigi, A., Kanekiyo, M., Boyoglu-Barnum, S., Myers, S. I., Tsybovsky, Y., Wheatley, A. K., Schramm, C. A., et al. (2019) · mBio · doi:10.1128/mbio.02810-18 · Cited by 144
Complete mapping of viral escape from neutralizing antibodies
Doud, M. B., Hensley, S. E., & Bloom, J. D. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006271 · Cited by 133
Self-citationLeon, P. E., He, W., Mullarkey, C. E., Bailey, M. J., Miller, M. S., Krammer, F., Palese, P., & Tan, G. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613225113 · Cited by 118
Schwartzman, L. M., Cathcart, A. L., Pujanauski, L. M., Qi, L., Kash, J. C., & Taubenberger, J. K. (2015) · mBio · doi:10.1128/mbio.01044-15 · Cited by 97
Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies
Arevalo, C. P., Sage, V. L., Bolton, M. J., Eilola, T., Jones, J. E., Kormuth, K. A., Nturibi, E. M., Balmaseda, Á., Gordon, A., Lakdawala, S. S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920321117 · Cited by 94
Self-citationGraham, B. S., Mascola, J. R., & Fauci, A. S. (2018) · JAMA · doi:10.1001/jama.2018.0345 · Cited by 81
Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility
Gouma, S., Kim, K., Weirick, M. E., Gumina, M. E., Branche, A. R., Topham, D. J., Martin, E. T., Monto, A. S., Cobey, S. E., & Hensley, S. E. (2020) · Nature Communications · doi:10.1038/s41467-020-18465-x · Cited by 67
Self-citationWillis, E., Pardi, N., Parkhouse, K., Mui, B. L., Tam, Y. K., Weissman, D., & Hensley, S. E. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5701 · Cited by 54
Self-citationNelson, M. I., Lloyd‐Smith, J. O., Simonsen, L., Rambaut, A., Holmes, E. C., Chowell, G., Miller, M. A., Spiro, D. J., Grenfell, B. T., & Viboud, C. G. (2018) · Epidemics · doi:10.1016/j.epidem.2018.10.004 · Cited by 43
Messenger RNA vaccines against SARS-CoV-2
Topol, E. J. (2021) · Cell · doi:10.1016/j.cell.2020.12.039 · Cited by 42
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice
Freyn, A. W., Pine, M., Rosado, V. C., Benz, M., Muramatsu, H., Beattie, M. B., Tam, Y. K., Krammer, F., Palese, P., Nachbagauer, R., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.003 · Cited by 37
Self-citationBrown, K. M., Sage, V. L., French, A. J., Jones, J. E., Padovani, G. H., Avery, A. J., Myerburg, M. M., Schultz‐Cherry, S., Rosch, J. W., Hiller, N. L., et al. (2022) · FEMS Microbes · doi:10.1093/femsmc/xtac007 · Cited by 21
Self-citation
Cited by
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina-Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 279
Self-citationFurey, C., Scher, G., Ye, N., Kercher, L., DeBeauchamp, J., Crumpton, J. C., Jeevan, T., Patton, C., Franks, J., Rubrum, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48555-z · Cited by 79
Self-citationKimura, T., Leal, J. M., Simpson, A., Warner, N. L., Berube, B. J., Archer, J. F., Park, S., Kurtz, R., Hinkley, T., Nicholes, K., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.017 · Cited by 52
Cui, X., Vervaeke, P., Gao, Y., Opsomer, L., Sun, Q., Snoeck, J., Devriendt, B., Zhong, Z., & Sanders, N. N. (2024) · npj Vaccines · doi:10.1038/s41541-024-00932-x · Cited by 33
Yuan, J., Chen, J., Zhao, Q., Xu, J., Li, X., Zhang, Y., Li, H., Chen, X., Zhao, L., Zhang, X., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1558482 · Cited by 8
Metadata
- Authors
- Arevalo, C. P., Bolton, M. J., Le Sage, V., Ye, N., Furey, C., Muramatsu, H., Alameh, M.-G., Pardi, N., Drapeau, E. M., Parkhouse, K., Garretson, T., Morris, J. S., Moncla, L. H., Tam, Y. K., Fan, S. H. Y., Lakdawala, S. S., Weissman, D., & Hensley, S. E.
- Venue
- Science
- Published
- 2022-11-25
- Volume
- 378
- Issue
- 6622
- Pages
- 899-904
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4310251723
- Cited by
- 358
- References
- 39
- FWCI
- 45.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.